CME: Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update.

Area of Science:

• Aesthetics
• Dermatology
• Plastic Surgery

Background:

• Botulinum toxin type A (BoNT-A) gained FDA approval for aesthetic use in 2002.
• Clinical evidence and understanding of facial anatomy have significantly advanced.
• BoNT-A use has expanded beyond the upper face to the midface, lower face, and neck.

Purpose of the Study:

• To discuss recent advances in BoNT-A use for facial aesthetics.
• To address the implications of new BoNT-A agents.
• To consider the impact of an evolving patient population on aesthetic treatments.

Main Methods:

• A multidisciplinary panel of 6 experts convened at the 2019 American Society for Dermatologic Surgery (ASDS) meeting.
• Experts included specialists in dermatology and plastic surgery.
• Discussions focused on minimally invasive injectable procedures.

Main Results:

• BoNT-A injections are the most common cosmetic procedure worldwide.
• Facial aesthetics trends show increasing patient diversity (age, gender, ethnicity).
• Advances in treatment planning and implementation have occurred.

Conclusions:

• BoNT-A remains a leading cosmetic procedure with expanding applications.
• New agents and diverse patient populations necessitate updated treatment strategies.
• Continued expert discussion is crucial for advancing facial aesthetic treatments.